GlassScriptPhysician profile
Kathryn Odom
NPI 1053865956
$3,721.64
in general payments reported to CMS, 2019-2025
27 companies · $1,460 in 2025
The $1,460 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $317 · 2022: $189 · 2023: $888 · 2024: $867 · 2025: $1,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,215.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $674.82 | 2021-2025 | |
| Inspire Medical Systems, INC. | $580.04 | 2022-2023 | Inspire |
| Viiv Healthcare Company | $437.22 | 2021-2025 | Apretude, Cabenuva, Dovato |
| Merck Sharp & Dohme LLC | $355.79 | 2021-2025 | Pifeltro, Delstrigo, Capvaxive |
| Axsome Therapeutics, INC. | $165.30 | 2023 | Sunosi |
| Melinta Therapeutics, LLC | $159.14 | 2024-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Insmed, INC. | $154.74 | 2024-2025 | Arikayce, Brinsupri |
| Paratek Pharmaceuticals, INC. | $139.38 | 2024-2025 | Nuzyra |
| La Jolla Pharmaceutical Company | $138.38 | 2021-2025 | Xerava, Zevtera |
| Harmony Biosciences LLC | $124.61 | 2023 | Wakix |
| Abbvie INC. | $107.69 | 2022-2025 | |
| Cumberland Pharmaceuticals, INC. | $90.33 | 2024-2025 | Vibativ |
| Napo Pharmaceuticals INC | $74.13 | 2021-2025 | Mytesi |
| Aimmune Therapeutics, INC. | $73.68 | 2025 | Vowst |
| Jazz Pharmaceuticals INC. | $64.25 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $58.88 | 2023 | Quviviq |
| Azurity Pharmaceuticals, INC. | $54.97 | 2023 | Horizant |
| Janssen Biotech, INC. | $54.12 | 2021 | |
| Cormedix INC. | $38.07 | 2025 | Defencath |
| Takeda Pharmaceuticals U.S.A., INC. | $34.06 | 2024 | Cuvitru |
| Pfizer INC. | $29.00 | 2025 | |
| Hologic Sales and Service, LLC | $23.89 | 2024 | Aptima |
| Tetraphase Pharmaceuticals, INC. | $22.57 | 2025 | |
| Ferring Pharmaceuticals INC. | $18.66 | 2024 | Rebyota |
| Janssen Scientific Affairs, LLC | $17.27 | 2021 | |
| Shionogi INC | $17.15 | 2025 | Fetroja |
| Emd Serono, INC. | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Odom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.